New brain tumor drug put to the test in tiny trial
NCT ID NCT06636162
First seen Mar 01, 2026 · Last updated May 09, 2026 · Updated 10 times
Summary
This early study tests an oral drug called DSP-0390 in 20 adults with IDH-mutant gliomas (a type of brain tumor) who are scheduled for surgery. Participants take the drug for about two weeks before their tumor is removed, allowing researchers to measure how much drug reaches the tumor and how it affects cholesterol-related pathways. The goal is to gather safety and drug-level data, not to treat the disease directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA, MALIGNANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.